Imperial College London
Portrait Picture

Dr Nick Powell

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Gastroenterology
 
 
 
//

Contact

 

nicholas.powell

 
 
//

Assistant

 

Mrs Heather Bones +44 (0)20 7594 2429

 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Powell:2021:10.1016/S2468-1253(20)30014-5,
author = {Powell, N and Ibraheim, H and Raine, T and Speight, A and Papa, S and Brain, O and Green, M and Samaan, MA and Spain, L and Yousaf, N and Hunter, N and Eldridge, L and Pavlidis, P and Irving, P and Hayee, B and Turajlic, S and Larkin, J and Lindsay, JO and Gore, M},
doi = {10.1016/S2468-1253(20)30014-5},
journal = {Lancet Gastroenterology and Hepatology},
pages = {679--697},
title = {British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis},
url = {http://dx.doi.org/10.1016/S2468-1253(20)30014-5},
volume = {5},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Immune checkpoint inhibitors (ICPis) are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonizing important inhibitory immune pathways, thereby augmenting immune mediated anti-tumour responses. However, immune activation is not cancer specific and often results in activation of immune cells in non-cancer tissues resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side effects of ICPi therapy. Prompt recognition of gastrointestinal toxicity and in many cases rapid institution of anti-inflammatory and/or biological therapy is required to reverse these complications. Optimal management of organ specific complications frequently requires engagement with gastroenterologists to deliver improved outcomes for patients developing ICPi-induced enterocolitis. In this British Society of Gastroenterology (BSG) endorsed guidance document we have developed a consensus framework for the investigation and management of ICPi-induced enterocolitis.
AU  - Powell,N
AU  - Ibraheim,H
AU  - Raine,T
AU  - Speight,A
AU  - Papa,S
AU  - Brain,O
AU  - Green,M
AU  - Samaan,MA
AU  - Spain,L
AU  - Yousaf,N
AU  - Hunter,N
AU  - Eldridge,L
AU  - Pavlidis,P
AU  - Irving,P
AU  - Hayee,B
AU  - Turajlic,S
AU  - Larkin,J
AU  - Lindsay,JO
AU  - Gore,M
DO  - 10.1016/S2468-1253(20)30014-5
EP  - 697
PY  - 2021///
SN  - 2468-1253
SP  - 679
TI  - British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
T2  - Lancet Gastroenterology and Hepatology
UR  - http://dx.doi.org/10.1016/S2468-1253(20)30014-5
UR  - http://hdl.handle.net/10044/1/77324
VL  - 5
ER  -
Download